Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/-rearranged myeloid/lymphoid neoplasm with mutation - diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib.

TitleLeukemic lineage switch in a t(8;22)(p11.2;q11.2)/-rearranged myeloid/lymphoid neoplasm with mutation - diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib.
Publication TypeJournal Article
Year of Publication2020
AuthorsManur R, Sung PJ, Loren AW, Ritchie EK, Frank D, Bagg A, Geyer JT, Bogusz AM
JournalLeuk Lymphoma
Volume61
Issue2
Pagination450-454
Date Published2020 02
ISSN1029-2403
KeywordsCore Binding Factor Alpha 2 Subunit, Gene Rearrangement, Humans, Leukemia, Myeloid, Male, Middle Aged, Morpholines, Mutation, Pyrimidines, Pyrroles, Receptor, Fibroblast Growth Factor, Type 1, Translocation, Genetic
DOI10.1080/10428194.2019.1660975
Alternate JournalLeuk Lymphoma
PubMed ID31524018
Related Faculty: 
Julia Geyer, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700